Actively Recruiting

Age: 18Years - 65Years
All Genders
NCT06393894

Latvian Early Atherosclerosis Registry

Led by Pauls Stradins Clinical University Hospital · Updated on 2024-05-01

100

Participants Needed

1

Research Sites

613 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Atherosclerosis and its complications are a global problem. There are several widely known and proven risk factors that promotes atherogenesis in the majority of patients. However, significant proportion of apparently healthy and young patients with cardiovascular disease but yet without recognized atherogenesis promoting risk factors can be observed in clinical practice. It highlights the need of new risk markers for early atherosclerosis diagnostics to prevent serious cardiovascular complications in these patients and in population in general. The interest in the negative impact of genetic variance, gene regulation on atherogenesis is growing. Therefore the purpose of this study is to analyze the impact of genetic variance and microRNA expression on early atherosclerosis development in the population of young, apparently healthy patients with coronary atherosclerosis. The primary hypothesis is that the group of patients with premature atherosclerosis have common genetic variations promoting early atherosclerosis development. The secondary hypothesis is that specific circulating microRNA expression (miR-126, miR-145 and miR-155) correlate with plaque lipid core by near infrared spectroscopy (NIRS) analysis.

CONDITIONS

Official Title

Latvian Early Atherosclerosis Registry

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Signed informed consent
  • Early atherosclerosis defined as coronary atherosclerosis in men aged <55 years and women <65 years
  • Coronary artery atherosclerosis with angiographically proven coronary vessel luminal stenosis ≥ 50% and ischaemia
  • Coronary artery atherosclerosis with planned revascularization
  • History of coronary artery revascularization (PTCA or coronary artery bypass surgery)
  • Coronary vessel suitable for NIRS pullback
Not Eligible

You will not qualify if you...

  • Diabetes
  • Total cholesterol ≥7 mmol/l and/or LDL ≥5 mmol/l
  • Family hypercholesterolemia
  • Positive family history of early cardiovascular disease (myocardial infarction, sudden cardiac death or cardiovascular disease of first degree relatives at young age - men <55 years, women <65 years)
  • Malignant or resistant hypertension ≥10 years
  • Body mass index ≥40 kg/m2
  • 20 or more pack years of smoking

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Pauls Stradins Clinical University hospital

Riga, Latvia

Actively Recruiting

Loading map...

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here